Fig. 5: RIPK3 expression augments dl922-947-induced cytotoxicity in vivo

a Expression of RIPK3 does not alter subcutaneous growth of HeLa tumours in female nude mice (N = 14 for LZRS, 28 for RIPK3). Data represent mean ± SEM. b HeLa-RIPK3 tumours retain expression of RIPK3 by qRT-PCR (left) and immunoblot (right). c HeLa-RIPK3 (clones D2 and E4) and HeLa-LZRS tumours were injected with a single intratumoural dose of dl922-947 (5 × 10⁹ particles) and harvested 48 h later. Expression of E1A and Ad5 proteins was assessed by quantitative IHC. d Necrotic area was quantified using Slidepath Tissue Image Analysis. *p < 0.05. e HeLa-RIPK3 (clone D2) and HeLa-LZRS tumours were grown subcutaneously in CD1 female nude mice (n = 12 per genotype). Once tumours reached approximately 200 mm³ (median 195 mm³ for LZRS, 185 mm³ for RIPK3), mice were randomly allocated to receive two doses of intratumoural dl922-947 (5 × 10⁹ particles) or PBS, 14 days apart. Tumours were measured twice weekly by callipers. Error bars represent SEM. *p < 0.05